ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Gilead gets FDA breakthrough therapy status for magrolimab in MDS
September 18, 2020Gilead Sciences has been given breakthrough therapy designation for magrolimab from the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS) in newly diagnosed patients. -
Gilead to Acquire Immuno-Oncology Company Forty Seven for $4.9 Billion
March 04, 2020Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. -
Gilead to Acquire Forty Seven for $4.9B
March 03, 2020Will gain lead product candidate magrolimab in clinical development for the treatment of several cancers.
Pharma Sources Insight January 2025
